

REMARKS

I. THE STATUS OF THE CLAIMS

Claims 1, 3, 6 and 8-10 are pending in the application. Claim 1 is amended to be commensurate with the example in the specification. Support for the amendment can be found in the specification at, for example, paragraphs [0060], [0083] and [0108].

II. THE REJECTIONS UNDER 35 U.S.C. § 103

The Office Action rejects claims 1, 3, 5, 6, 8-17, 19 and 23-27 under 35 U.S.C. § 103 as being obvious over Gowan (U.S. Patent No. 5,374,659), Gergely et al. (U.S. Patent No. 5,834,019), Patel et al. (U.S. Patent No. 6,569,463), Amselem et al. (U.S. Patent No. 5,747,061), Gergeley et al. (U.S. Patent No. 5,527,540); McNamara et al. (U.S. Patent No. 6,423,298) and Hagemann et al. (U.S. Patent No. 5,211,957). Applicants respectfully traverse the rejection.

Applicants submit the references cited do not disclose the use of a pharmaceutical composition having the particular ingredients or amounts thereof as claimed.

Reconsideration and withdrawal of the rejection of claims 1, 3, 5, 6, 8-17, 19 and 23-27 under 35 U.S.C. § 103 are respectfully requested.

IV. Conclusion

Early consideration and prompt allowance of the claims are respectfully requested. If there are any fees due in connection with the filing of this response, please charge the fees to our Deposit Account No. 10-0750/MCP5017US/LAD.

Respectfully submitted,

By: /Laura A. Donnelly/
Laura A. Donnelly
Reg. No. 38,435

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-1729